Two different people asked me about two different NASH/MASH drugs.
My response -
My response -
Quote:Very good results for Survodutide. The mechanism of action of activating GLP-1 is the same as Ozempic. Over time you might see some of the same side effects develop.
The other real competitor out there is Rezdiffra. That drug activates the thyroid hormone THR-b. In a past post I wondered about long terms effects of overactivating a hormone that highly elevates energy burn rates. It has shown serious adverse events in the liver and gall bladder.
In both cases the drugs are targeted directly at eliminating fat. I think leronlimab can beat Rezdiffra. With Survodutide it might equal it or possibly beat it if the cause of non-responders could be found.
I decided to look back at leronlimab's trial in NASH to see if possibly my theory of a single allele CCR5 delta 32 deletion in some patients may be the cause. What is interesting is that in the 350mg arm there were 16 Hispanic/African American patients and 6 Caucasian, non-Hispanics. In the 750mg arm there were 9 Hispanics/ 0 African Americans and 13 Caucasian, non-Hispanics.
Hispanics and African Americans show around a 3% expression of a single allelle CCR5 delta 32 deletion vs. around 15% for Caucasian, non-Hispanics. With the much lower number of Caucasian, non-Hispanics in the 350mg arm and the higher number of Caucasian, non-Hispanics in the 750mg arm there is a very good chance that there were no single allele CCR5 delta 32 single allele patients in the 350mg arm and two single allele patients in the 750mg arm. With only 22 patients in each arm that could skew results dramatically.
Now I'd like to find out if they excluded only patients with the double allele or patients with the double allele and single allele. If they excluded only the double allele patients then we may have solved the problem of non-responders.
17
